See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

Oncternal's autologous CAR T therapy ONCT-808 cleared to enter clinic for aggressive B-cell NHL

Oct. 4, 2022
Oncternal Therapeutics Inc. has received IND clearance from the FDA for a phase I/II study of ONCT-808.
BioWorld Science CAR T Cancer CAR T Immuno-oncology FDA IND